IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice

Abstract

These data indicate that obesity-driven activation of the IL-17 axis is central to the development and progression of NAFLD to steatohepatitis and identify the IL-17 pathway as a novel therapeutic target in this condition.